<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OSaIpzzie41wpzLe3jsrMkGfrXmd8Bxejquc_cfVAKNHYAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OSaIpzzie41wpzLe3jsrMkGfrXmd8Bxejquc_cfVAKNHYAA/641"/>
Leidi Network, Lei Jianping, April 15
TransThera Biosciences (Nanjing) Co., Ltd. (abbreviated as &#34;TransThera&#34;, stock code: 2617) conducted a placement today at a price of HKD 57.03, placing 5.085 million shares.
The placement price of HKD 57.03 per share represents a discount of approximately 18% to the closing price of HKD 69.55 per H share on April 14, 2026; and a discount of approximately 19.20% to the average closing price of HKD 70.58 per H share reported on the Stock Exchange for the five consecutive trading days ending April 13, 2026.
TransThera expects the total amount raised from the placement and the net proceeds to be approximately HKD 290 million and HKD 282 million, respectively.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OhO_psnH64FKI8GlkfAFAKs6Ksio_ba-GT7p9pL2R4ciUAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OhO_psnH64FKI8GlkfAFAKs6Ksio_ba-GT7p9pL2R4ciUAA/641"/>
The 5.085 million shares placed under the placement represent approximately 1.67% of the existing issued H shares as of the date of this announcement and 1.27% of the existing issued shares, and approximately 1.65% of the issued H shares and approximately 1.26% of the issued shares after the completion of the placement (assuming all placement shares are fully placed).
Just raised HKD 190 million, investors are down 27%
TransThera was listed on the Hong Kong Stock Exchange in June 2025. The issue price was HKD 13.15, issuing 15.281 million shares, raising a total of HKD 200 million; after deducting issuance costs of HKD 39.61 million, the net proceeds were HKD 161 million.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OKhHksT9fIdP6H2fNmZFcvAv9q6DIxDO3Nt7QX9B_BmV8AA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OKhHksT9fIdP6H2fNmZFcvAv9q6DIxDO3Nt7QX9B_BmV8AA/641"/>
TransThera's cornerstone investors include Jiangbei Pharmaceutical, CanSino Biologics, Washington Holdings, TransThera Horizon, and Kylin Capital, with a total subscription of HKD 130 million.
In January 2026, TransThera completed the placement at a price of HKD 92.85, issuing 2.1 million shares, and after deducting placement commissions and other costs, the net proceeds were HKD 190 million.
Based on today's midday price of HKD 68, investors who participated in January 2026 are down 26.76%.
No revenue, annual loss of HKD 300 million
TransThera recently released its financial report. The report shows that TransThera had no revenue in 2025, with a gross profit of 0 and R&amp;D expenses of HKD 247 million
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OMo2OK_kyZmZcB_EckDCiayyyUzdupyb8yrZjNI7U4VnEAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OMo2OK_kyZmZcB_EckDCiayyyUzdupyb8yrZjNI7U4VnEAA/641"/>
TRANSTHERA-B's loss for the year 2025 is 296 million yuan, compared to a loss of 275 million yuan in the same period last year.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OTQsPQmtl9QU_VAwUJIuvv0GSDOLwlont4nTOCJbLEvC0AA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OTQsPQmtl9QU_VAwUJIuvv0GSDOLwlont4nTOCJbLEvC0AA/641"/>
TRANSTHERA-B's total non-current assets for 2025 amount to 45.05 million yuan, current assets total 500 million yuan, and total equity is 416 million yuan.
———————————————
Leidi was founded by media person Lei Jianping. Please indicate the source if reprinted

02617

159992

159506

TRANSTHERA (Stock Code: 2617) conducted a placement today, raising approximately HKD 280 million, with a placement price of HKD 57.03, representing a discount of about 18% to the market price. The company expects no revenue in 2025, with a loss of approximately HKD 300 million. Research and development expenses for 2025 are projected to be HKD 247 million, with losses for the year increasing compared to the previous year. The company's asset situation shows non-current assets of HKD 45.05 million, current assets of HKD 500 million, and total equity of HKD 416 million

腾讯新闻 - 财经

TRANSTHERA-B

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

HKEX

AKESO

PHARMABLOCK

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

TRANSTHERA-B conducts a placement: raising HKD 280 million with no revenue in 2025, losing HKD 300 million